1311393-03-9Relevant articles and documents
Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid
Hieke, Martina,Greiner, Christine,Dittrich, Michaela,Reisen, Felix,Schneider, Gisbert,Schubert-Zsilavecz, Manfred,Werz, Oliver
, p. 4490 - 4507 (2011/09/15)
Various inflammatory diseases are associated with the excessive formation of leukotrienes (LTs) and prostaglandins (PGs). Herein, we present a novel class of dual inhibitors of 5-lipoxygenase (5-LO) and microsomal prostaglandin E 2 synthase-1 (
SAR studies of acidic dual γ-secretase/PPARγ modulators
Hieke, Martina,Ness, Julia,Steri, Ramona,Greiner, Christine,Werz, Oliver,Schubert-Zsilavecz, Manfred,Weggen, Sascha,Zettl, Heiko
, p. 5372 - 5382 (2011/10/12)
A novel set of dual γ-secretase/PPARγ modulators characterized by a 2-benzyl hexanoic acid scaffold is presented. Synthetic efforts were focused on the variation of the substitution pattern of the central benzene. Finally, we obtained a new class of 2,5-disubstituted 2-benzylidene hexanoic acid derivatives, which act as dual γ-secretase/PPARγ modulators in the low micromolar range. We have explored broad SAR and successfully improved the dual pharmacological activity and the selectivity profile against potential off-targets such as NOTCH and COX. Compound 17 showed an IC50 Aβ42 = 2.4 μM and an EC50 PPARγ = 7.2 μM and could be a valuable tool to further evaluate the concept of dual γ-secretase/ PPARγ modulators in animal models of Alzheimer's disease.